Overview
NRIX market data
Price History
NRIX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.79 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -928.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.20 – $26.36 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7B · P/B 3.18 · P/S 73.05.
Company News
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36Benzinga · Aug 10, 2026, 4:28 PM
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price TargetBenzinga · Aug 4, 2026, 3:08 PM
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911Benzinga · Aug 4, 2026, 11:14 AM
Nurix Therapeutics Enrolls First Patient In Registrational Phase 3 DAYBreak CLL-306 Trial Of Bexobrutideg For Relapsed/Refractory CLL/SLLBenzinga · Aug 4, 2026, 5:21 AM
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38Benzinga · Jul 28, 2026, 5:00 PM
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsightGlobenewswire Inc · Jul 23, 2026, 5:15 PM
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31Benzinga · Jul 22, 2026, 6:45 PM
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%Benzinga · Jul 21, 2026, 8:07 PM
Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone PaymentsBenzinga · Jul 21, 2026, 8:06 PM
Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting PeriodBenzinga · Jul 21, 2026, 8:03 PM